The United States saw a significant change in cannabis regulation on Thursday as President Donald Trump’s acting attorney general authorized the reclassification of state-licensed medical marijuana.

Federal Reclassification of Medical Marijuana

This decision downgrades the drug’s scheduling from Schedule I – reserved for substances with no accepted medical use and a high potential for abuse – to a less restrictive category. The announcement was made by Todd Blanche via social media, and a formal hearing is scheduled for June 29th to further discuss the reclassification process.

Impact on Research and Patient Access

The reclassification acknowledges the potential therapeutic benefits of cannabis and aims to ease barriers to research and patient access. Currently, forty states have medical marijuana programs, and this federal action lends legitimacy to these state-level initiatives.

State-licensed cannabis producers and distributors will find it easier to register with the Drug Enforcement Administration (DEA), leading to a more regulated industry. Researchers will no longer face penalties for using state-licensed cannabis in their studies, which is expected to spur scientific investigation into the drug’s efficacy.

Financial Benefits for the Cannabis Industry

Cannabis businesses will now be permitted to deduct ordinary business expenses on their federal taxes, a change previously prohibited due to the Schedule I classification. This is anticipated to provide a financial boost, allowing for reinvestment in research, development, and expansion.

Reactions to the Announcement

Michael Bronstein, president of the American Trade Association for Cannabis and Hemp, called the move “the most significant federal advancement in cannabis policy in over 50 years.” However, Kevin Sabet, chief executive of Smart Approaches to Marijuana, strongly disapproved, calling the Trump administration “the most pro-drug administration in our history.”

Sabet expressed concern that commercial interests within the cannabis industry are unduly influencing policy decisions. The upcoming hearing on June 29th will be a pivotal moment in the ongoing debate surrounding cannabis legalization and regulation.

While the reclassification does not address recreational marijuana, it is viewed as a potential step towards broader federal reforms. This change occurred alongside other news in Utah, including a major interstate closure and legal proceedings at Brigham Young University.